SCHEMBL25357192

SCHEMBL25357192

OB(O)c1ccc(C#CCCN2CCCCC2)nc1

nearest known ligand 0.47

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 17/20 0.47
▸ KMT2A Q03164 1/20 0.42
▸ DRD2 P14416 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ MCHR1 Q99705 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31360978 0.81 MCHR1 (0.46) HRH3KMT2ADRD2DRD4DRD3
SCHEMBL25997020 0.80 HRH3 (0.50) HRH3KMT2ADRD2DRD4DRD3
SCHEMBL1864727 0.78 HRH3 (0.63) HRH3
SCHEMBL29547177 0.74 ALDH1A1 (0.35) —
SCHEMBL20120404 0.74 ALDH1A1 (0.35) —
SCHEMBL25355748 0.70 HRH3 (0.63) HRH3
SCHEMBL29550640 0.70 HRH3 (0.52) HRH3KMT2A
SCHEMBL25997024 0.67 HRH3 (0.45) HRH3DRD2DRD4DRD3
SCHEMBL1857487 0.65 HRH3 (0.54) HRH3KMT2A
SCHEMBL2549507 0.64 HRH3 (0.65) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119954828-A Parallel ring compound and preparation and application thereof 石药集团中奇制药技术(石家庄)有限公司 2025-05-09 — — CN disclosed
CN-116322699-B Parallel ring compound and preparation and application thereof 石药集团中奇制药技术(石家庄)有限公司 2025-02-11 — — CN disclosed
US-20240294545-A1 A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) 2024-09-05 — — US disclosed
EP-4219499-A1 A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2023-08-02 — — EP disclosed
EP-4219499-A1 A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2023-08-02 — — EP disclosed
CN-116322699-A Parallel ring compound and preparation and application thereof 石药集团中奇制药技术(石家庄)有限公司 2023-06-23 — — CN disclosed
WO-2022063303-A1 A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF 石药集团中奇制药技术(石家庄)有限公司 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294545-A1 A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF ATM, CHEK2, CHEK1 HRH3 2978/4885KMT2A 1137/4885DRD2 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback